Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasms 2Multiple Myeloma 2Solid Tumors 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms, Plasma Cell 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

fludarabine phosphate 20Peripheral Blood Stem Cell Transplantation 20Cyclophosphamide 17Busulfan 16ruxolitinib 14Tacrolimus 12Whole-Body Irradiation 9Mycophenolic Acid 9Methotrexate 8Antilymphocyte Serum 8Cyclosporine 7peginterferon alfa-2a 6Hydroxyurea 6Filgrastim 6Etoposide 6Aspirin 6fludarabine 5Prednisone 5Melphalan 5Imatinib Mesylate 5Cytarabine 5Decitabine 4pomalidomide 3givinostat hydrochloride 3givinostat 3Topotecan 3Thiotepa 3Radiotherapy 3Lenalidomide 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Polycythemia Vera × LCL161 × Clear all
NCT02098161 2023-06-06

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

M.D. Anderson Cancer Center

Phase 2 Completed
50 enrolled 11 charts
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡